4results about How to "Increased cleavage" patented technology

The utility model discloses a forestry branch pruning device, which relates to the technical field of pruning devices and comprises a movable base component and a driving component arranged on the top surface of the movable base component, a collecting component is arranged on one side of the driving component, and a pruning component is further arranged on the top surface of the movable base component. The driving assembly comprises a mounting plate fixedly connected to the top of the movable base assembly, a push handle is fixedly connected to one side of the mounting plate, a first fixing plate is fixedly connected to one side of the mounting plate, a first motor is arranged on the top of the first fixing plate, a first lead screw is rotationally connected to one side of the first fixing plate, and the first lead screw is connected with the output end of the first motor. According to the arrangement, the pruning assembly in the device is utilized to quickly and automatically prune and cut off branches, the situation that time and labor are wasted due to the fact that a worker holds a pruning knife component to work is avoided, operation is easy and quick, and the pruning work efficiency of the device is improved.

Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

A novel pharmaceutical composition for treating ALS is provided comprising as the active ingredient an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4. A pharmaceutical composition for treating ALS comprising an anti-EphA4 antibody is provided, wherein the anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 44, a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 27, and a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 28, and a light chain comprising a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 29, a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 30, and a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 31.

Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.